Michael Osthoff
Overview
Explore the profile of Michael Osthoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
987
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scheer C, Giamarellos-Bourboulis E, Ferrer R, Idelevich E, Annane D, Artigas A, et al.
Am J Respir Crit Care Med
. 2025 Jan;
PMID: 39787606
Rationale: Early detection, standardized therapy, adequate infrastructure and strategies for quality improvement should constitute essential components of every hospital's sepsis plan. Objectives: To investigate the extent to which recommendations from...
2.
Boesing M, Albrich W, Bridevaux P, Charbonnier F, Clarenbach C, Fellrath J, et al.
Praxis (Bern 1994)
. 2024 Dec;
113(11-12):297-305.
PMID: 39697155
In Switzerland, additional vaccinations against influenza, COVID-19, Streptococcus pneumoniae and varicella zoster virus (VZV), are recommended for patients with chronic lung diseases such as COPD, asthma or interstitial lung disease,...
3.
4.
Jost L, Helmchen B, Osthoff M, Nigg Calanca L
Cureus
. 2024 Nov;
16(10):e72113.
PMID: 39575061
We present a severe case of hypocomplementemic urticarial vasculitis syndrome (HUVS) and its diagnostic and therapeutic challenges. A 56-year-old male presenting with fever and impaired kidney function was diagnosed with...
5.
Rentsch K, Khanna N, Halbeisen D, Osthoff M
Antibiotics (Basel)
. 2024 Oct;
13(10).
PMID: 39452236
: Narrow-spectrum beta-lactam antibiotics such as benzylpenicillin and flucloxacillin are increasingly used in outpatient parenteral antimicrobial therapy (OPAT) programs to mitigate the adverse effects associated with broad-spectrum antibiotics. These beta-lactams...
6.
Bausch S, Drager S, Charitos-Fragkakis P, Egli A, Moser S, Hinic V, et al.
Antibiotics (Basel)
. 2024 Oct;
13(10).
PMID: 39452195
This study aimed to determine cefazolin target attainment in patients with invasive () infections and to develop a population pharmacokinetic (PK) model. Adult patients with invasive infections treated with cefazolin...
7.
Moser S, Araschmid L, Panagiotou A, Bonati L, Breidthardt T, Fahrni G, et al.
Biomedicines
. 2024 Sep;
12(9).
PMID: 39335470
Background: Acute kidney injury (AKI) as a result of iodinated contrast media (CM) has been linked to CM-induced renal ischemia and toxic effects on endothelial cells (EC). The recombinant human...
8.
Drager S, Ewoldt T, Abdulla A, Rietdijk W, Verkaik N, van Vliet P, et al.
J Crit Care
. 2024 Sep;
85:154904.
PMID: 39277523
Objectives: This study aims to assess pharmacodynamic target attainment in critically ill patients and identify factors influencing target attainment and mortality outcomes. Methods: We analysed data from the DOLPHIN trial....
9.
Muller S, Kaumanns A, Adam K, Osthoff M, Drager S
Am J Case Rep
. 2024 Aug;
25:e944508.
PMID: 39182163
BACKGROUND Common causes of severely elevated transaminases, especially alanine transaminase, due to liver diseases include drug-induced liver injury and acute viral hepatitis, especially hepatitis E, which can present similarly in...
10.
Blickenstorfer Y, Jirasko V, Tanno A, Drager S, Hoven D, Lohle J, et al.
Biosens Bioelectron
. 2024 Jul;
262:116524.
PMID: 38971036
The lateral flow assay (LFA) is an ideal technology for at-home medical diagnostic tests due to its ease of use, cost-effectiveness, and rapid results. Despite these advantages, only few LFAs,...